Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
暂无分享,去创建一个
Ian D Pavord | Peter Howarth | Stephanie Korn | Roland Buhl | Oliver N Keene | I. Pavord | E. Bleecker | P. Howarth | O. Keene | P. Chanez | S. Korn | R. Buhl | Eugene R Bleecker | Hector O Ortega | Pascal Chanez | Hector Ortega | Hector Ortega
[1] Nicola A Hanania,et al. Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.
[2] Christopher E Brightling,et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.
[3] P. Gibson,et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial , 2011, The Lancet.
[4] C. Brightling,et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry , 2010, Thorax.
[5] I. Pavord,et al. Mepolizumab in refractory eosinophilic asthma , 2010, Thorax.
[6] D. Curran‐Everett,et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.
[7] Parameswaran Nair,et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.
[8] Ana Sousa,et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.
[9] Mike Thomas,et al. Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.
[10] J A Anderson,et al. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited , 2008, European Respiratory Journal.
[11] W. Busse,et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.
[12] W. Busse,et al. Severe asthma in adults: what are the important questions? , 2007, The Journal of allergy and clinical immunology.
[13] A. Vignola,et al. Near‐fatal asthma phenotype in the ENFUMOSA Cohort , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[14] L. Boulet,et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.
[15] Klas Svensson,et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.
[16] Stephen T Holgate,et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. , 2004, American journal of respiratory and critical care medicine.
[17] S. Phipps,et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.
[18] A. Kay,et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.
[19] I. Pavord,et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.
[20] P Godard,et al. Costs of asthma are correlated with severity: a 1-yr prospective study , 2002, European Respiratory Journal.
[21] K. Chung,et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.
[22] S. Spector,et al. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. , 2000, American journal of respiratory and critical care medicine.
[23] G H Guyatt,et al. Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.
[24] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[25] P. Barnes,et al. The costs of asthma. , 1996, The European respiratory journal.
[26] G. Guyatt,et al. Measuring quality of life in asthma. , 1993, The American review of respiratory disease.
[27] A. Adinoff,et al. Steroid-induced fractures and bone loss in patients with asthma. , 1983, The New England journal of medicine.